Skip to main content
Erschienen in: World Journal of Surgery 7/2005

01.07.2005

Clinicopathological Factors Predicting Long-term Overall Survival after Hepatectomy for Peripheral Cholangiocarcinoma

verfasst von: Yi-Yin Jan, M.D., Chun-Nan Yeh, M.D., Ta-Sen Yeh, M.D., PhD., Hwang Tsann-Long, M.D., Miin- Fu Chen, M.D.

Erschienen in: World Journal of Surgery | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Abstract

Peripheral cholangiocarcinoma (PCC) is clinically challenging because patients typically do not present until the disease is relatively advanced. Three-year to 5-year survival rates even with resection thus remain dismal. This study aimed to determine the clinicopathological factors for predicting overall survival longer than 5 years in PCC patients treated with hepatectomy. From 1977 to 1997, the clinicopatholgical features of 11 PCC patients who underwent hepatectomy with long-term overall survival (group A) were reviewed. Comparison was made with the clinical features and factors influencing the outcome of 70 PCC patients who survived less than 5 years after hepatectomy (group B). Of 81 PCC patients undergoing hepatectomy, 11 (13.6%) were 5-year survivors. The 81 PCC patients comprised 32 men and 49 women, with a mean age of 56.0 years (range: 34–83 years). Univariate analysis showed that female gender, absence of physical findings, a higher percentage of presence of mucobilia, early staged tumor, intraductal papillary tumor growth, and curative hepatic resection were more frequent in group A patients than group B patients. However, multivariate logistic regression analysis showed that absence of physical findings, presence of mucobilia, early staged tumor, and curative hepatic resection were the four independent factors differentiating group A from B patients. The 1-, 3-, 5-, and 10-year survival rates of the group A patients were 100%, 100%, 100%, and 40%, whereas those of the group B patients were 46.0%, 9.5%, 0%, and 0%, respectively. Absence of physical findings, presence of mucobilia, early staged tumor, and curative hepatectomy could independently predict PCC patients with long-term overall survival after hepatectomy.
Literatur
1.
Zurück zum Zitat Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J. Gastroenterol. Hepatol. 1999;14:1144–1149CrossRefPubMed Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J. Gastroenterol. Hepatol. 1999;14:1144–1149CrossRefPubMed
2.
Zurück zum Zitat Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer, Tokyo, Kanehara, 1997, 1st English edition Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer, Tokyo, Kanehara, 1997, 1st English edition
3.
Zurück zum Zitat Suzuki H, Isaji S, Pairojkul C, et al. Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan. J. Hepatobiliary Pancreat. Surg. 2000;7:206–211CrossRefPubMed Suzuki H, Isaji S, Pairojkul C, et al. Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan. J. Hepatobiliary Pancreat. Surg. 2000;7:206–211CrossRefPubMed
4.
Zurück zum Zitat Sirica AE, Gainey TW, Harrell MB, et al. Cholangiocarcinogenesis and biliary adaptation responses in hepatic injury. In Sirica AE, Longnecker DS, eds., Biliary and Pancreatic Ductal Epithelia—Pathobiology and Pathophysiology, New York, Marcel Dekker, 1997;229–290 Sirica AE, Gainey TW, Harrell MB, et al. Cholangiocarcinogenesis and biliary adaptation responses in hepatic injury. In Sirica AE, Longnecker DS, eds., Biliary and Pancreatic Ductal Epithelia—Pathobiology and Pathophysiology, New York, Marcel Dekker, 1997;229–290
5.
Zurück zum Zitat Chapman RW. Risk factors for biliary tract carcinogenesis. Ann. Oncol. 1999;10(Suppl 4):S308–S311CrossRef Chapman RW. Risk factors for biliary tract carcinogenesis. Ann. Oncol. 1999;10(Suppl 4):S308–S311CrossRef
6.
Zurück zum Zitat Chu KM, Lo CM, Liu CL, et al. Malignancy associated with hepatolithiasis. Hepatogastroenterology 1997;44:352–357PubMed Chu KM, Lo CM, Liu CL, et al. Malignancy associated with hepatolithiasis. Hepatogastroenterology 1997;44:352–357PubMed
7.
Zurück zum Zitat Su WC, Shiesh SC, Liu HS, et al. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-β, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig. Dis. Sci. 2001;46:1387–1392CrossRefPubMed Su WC, Shiesh SC, Liu HS, et al. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-β, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig. Dis. Sci. 2001;46:1387–1392CrossRefPubMed
8.
Zurück zum Zitat Chen TC, Nakanuma Y, Zen Y, et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology 2001;34:651–658CrossRefPubMed Chen TC, Nakanuma Y, Zen Y, et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology 2001;34:651–658CrossRefPubMed
9.
Zurück zum Zitat Ponsioen CIJ, Tytgat GNJ. Primary sclerosing cholangitis: a clinical review. Am J. Gastroenterol 1998;93:515–523CrossRefPubMed Ponsioen CIJ, Tytgat GNJ. Primary sclerosing cholangitis: a clinical review. Am J. Gastroenterol 1998;93:515–523CrossRefPubMed
10.
Zurück zum Zitat Harrison PM. Prevention of bile duct cancer in primary sclerosing cholangitis. Ann Oncol 1999;10(Suppl 4):S208–S211CrossRef Harrison PM. Prevention of bile duct cancer in primary sclerosing cholangitis. Ann Oncol 1999;10(Suppl 4):S208–S211CrossRef
11.
Zurück zum Zitat Komi N, Tamura T, Miyoshi Y. Histochemical and immunohistochemical studies on development of biliary carcinoma in forty-seven patients with choledochal cysts—special reference to intestinal metaplasia in the biliary duct. Jpn. J. Surg. 1985;15:273–278PubMed Komi N, Tamura T, Miyoshi Y. Histochemical and immunohistochemical studies on development of biliary carcinoma in forty-seven patients with choledochal cysts—special reference to intestinal metaplasia in the biliary duct. Jpn. J. Surg. 1985;15:273–278PubMed
12.
Zurück zum Zitat Imazu M, Iwai N, Tokiwa K, et al. Factors of biliary carcinogenesis in choledochal cysts. Eur. J. Paediatr. Surg. 2001;11:24–27CrossRef Imazu M, Iwai N, Tokiwa K, et al. Factors of biliary carcinogenesis in choledochal cysts. Eur. J. Paediatr. Surg. 2001;11:24–27CrossRef
13.
Zurück zum Zitat Weber SM, Jarnagin WR, Klimstra D. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am. Coll. Surg. 2001;193:384–391CrossRefPubMed Weber SM, Jarnagin WR, Klimstra D. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am. Coll. Surg. 2001;193:384–391CrossRefPubMed
14.
Zurück zum Zitat Uenishi T, Hirohashi K, Kubo S. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J. Surg. 2001;25:865–869CrossRefPubMed Uenishi T, Hirohashi K, Kubo S. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J. Surg. 2001;25:865–869CrossRefPubMed
15.
Zurück zum Zitat Jarnagin WR, Fong Y, DeMatteo RP. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 2001;234:507–519CrossRefPubMed Jarnagin WR, Fong Y, DeMatteo RP. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 2001;234:507–519CrossRefPubMed
16.
Zurück zum Zitat De Groen CP, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N. Engl. J. Med. 1999;341:1368–1378CrossRefPubMed De Groen CP, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N. Engl. J. Med. 1999;341:1368–1378CrossRefPubMed
17.
Zurück zum Zitat Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353–1357CrossRefPubMed Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353–1357CrossRefPubMed
18.
Zurück zum Zitat Shirabe K, Shimada M, Harimoto N. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery 2002;131:S159–S164CrossRefPubMed Shirabe K, Shimada M, Harimoto N. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery 2002;131:S159–S164CrossRefPubMed
19.
Zurück zum Zitat Bathe OF, Pacheco JT, Ossi PB. Management of hilar bile duct carcinoma. Hepatogastroenterlogy 2001;48:1289–1294 Bathe OF, Pacheco JT, Ossi PB. Management of hilar bile duct carcinoma. Hepatogastroenterlogy 2001;48:1289–1294
20.
Zurück zum Zitat Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000;27:69:1633–1637CrossRef Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000;27:69:1633–1637CrossRef
21.
Zurück zum Zitat Tajima Y, Kuroki T, Fukuda K, et al. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br. J. Surg. 2004;91:99–104CrossRefPubMed Tajima Y, Kuroki T, Fukuda K, et al. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br. J. Surg. 2004;91:99–104CrossRefPubMed
22.
Zurück zum Zitat Morimoto Y, Tanaka Y, Ito T, et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Surg. 2003;10:432–440CrossRefPubMed Morimoto Y, Tanaka Y, Ito T, et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Surg. 2003;10:432–440CrossRefPubMed
23.
Zurück zum Zitat Uenishi T, Hirohashi K, Kubo S, et al. Clinicopathologic features in patients with long-term survival following resection for intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2003;50:1069–1072PubMed Uenishi T, Hirohashi K, Kubo S, et al. Clinicopathologic features in patients with long-term survival following resection for intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2003;50:1069–1072PubMed
24.
Zurück zum Zitat Uenishi T, Hirohashi K, Kubo S, et al. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J. Surg. 2001; 25:865–869CrossRefPubMed Uenishi T, Hirohashi K, Kubo S, et al. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J. Surg. 2001; 25:865–869CrossRefPubMed
25.
Zurück zum Zitat Isa T, Kusano T, Shimoji H, et al. Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma. Am. J. Surg. 2001;181:507–511CrossRefPubMed Isa T, Kusano T, Shimoji H, et al. Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma. Am. J. Surg. 2001;181:507–511CrossRefPubMed
26.
Zurück zum Zitat Kokudo N, Makuuchi M. Extent of resection and outcome after curative resection for intrahepatic cholangiocarcinoma. Surg. Oncol. Clin. North Am. 2002;11:969–983CrossRef Kokudo N, Makuuchi M. Extent of resection and outcome after curative resection for intrahepatic cholangiocarcinoma. Surg. Oncol. Clin. North Am. 2002;11:969–983CrossRef
27.
Zurück zum Zitat Nakanuma Y, Hoso M, Terada T. Clinical and pathologic features of cholangiocarcinoma. In Okuda K, Tabor E, eds., Liver Cancer, 1st edition, New York, Churchill Livingstone, 1997;279–290 Nakanuma Y, Hoso M, Terada T. Clinical and pathologic features of cholangiocarcinoma. In Okuda K, Tabor E, eds., Liver Cancer, 1st edition, New York, Churchill Livingstone, 1997;279–290
28.
Zurück zum Zitat Chen MF. Mucobilia: the clinical spectrum, diagnosis and treatment. J. Gastroenterol. Hepatol. 1998;13:1084–1090PubMed Chen MF. Mucobilia: the clinical spectrum, diagnosis and treatment. J. Gastroenterol. Hepatol. 1998;13:1084–1090PubMed
29.
Zurück zum Zitat Chen MF, Jan YY, Chen TS. Clinical studies of mucin-producing cholangiocarcinoma. A study of 22 histopathology-proven cases. Ann. Surg. 1998;227:63–69CrossRefPubMed Chen MF, Jan YY, Chen TS. Clinical studies of mucin-producing cholangiocarcinoma. A study of 22 histopathology-proven cases. Ann. Surg. 1998;227:63–69CrossRefPubMed
30.
Zurück zum Zitat Jan YY, Jeng LB, Hwang TL, et al. Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepatogastoenterology 1996;43:614–619 Jan YY, Jeng LB, Hwang TL, et al. Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepatogastoenterology 1996;43:614–619
31.
Zurück zum Zitat Cartel RB, Brausch JW, Kahn F. Polypoid epithelial tumors of the bile duct. N. Engl. J. Med. 1962;226:57–61 Cartel RB, Brausch JW, Kahn F. Polypoid epithelial tumors of the bile duct. N. Engl. J. Med. 1962;226:57–61
32.
Zurück zum Zitat Suh KS, Roh HR, Koh YT, et al. Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology 2000;31:12–17CrossRefPubMed Suh KS, Roh HR, Koh YT, et al. Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology 2000;31:12–17CrossRefPubMed
33.
Zurück zum Zitat Buskirk S, Gunderson L, Adson M, et al. Analysis of failure following curative irradiation of gallbladder and extrahepatic bile duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1984;10:2013–2023PubMed Buskirk S, Gunderson L, Adson M, et al. Analysis of failure following curative irradiation of gallbladder and extrahepatic bile duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1984;10:2013–2023PubMed
34.
Zurück zum Zitat Yeh CN, Jan YY, Yeh TS, et al. Hepatic resection of intraductal papillary type of cholangiocarcinoma. Ann. Surg. Oncol. 2004;11:606–611CrossRefPubMed Yeh CN, Jan YY, Yeh TS, et al. Hepatic resection of intraductal papillary type of cholangiocarcinoma. Ann. Surg. Oncol. 2004;11:606–611CrossRefPubMed
35.
Zurück zum Zitat Okabayashi T, Yamamoto J, Kosuge T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001;92:2374–2383CrossRefPubMed Okabayashi T, Yamamoto J, Kosuge T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001;92:2374–2383CrossRefPubMed
Metadaten
Titel
Clinicopathological Factors Predicting Long-term Overall Survival after Hepatectomy for Peripheral Cholangiocarcinoma
verfasst von
Yi-Yin Jan, M.D.
Chun-Nan Yeh, M.D.
Ta-Sen Yeh, M.D., PhD.
Hwang Tsann-Long, M.D.
Miin- Fu Chen, M.D.
Publikationsdatum
01.07.2005
Erschienen in
World Journal of Surgery / Ausgabe 7/2005
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-005-7763-7

Weitere Artikel der Ausgabe 7/2005

World Journal of Surgery 7/2005 Zur Ausgabe

BriefCommunication

Invited Commentary

OriginalPaper

Invited Commentary

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.